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a b s t r a c t
We recently characterized SEC62 as an oncogene in non-small-cell lung cancer (NSCLC).
Here we aimed to gain further insight into the molecular mechanisms of the cancer-related
functions of this oncogene. We performed 2D-DIGE proteome analysis of tumor material
from patients with NSCLC and of HEK293 cells stably overexpressing plasmid-encoded
SEC62, combined with investigation of the Sec62 interactome. Furthermore, we analyzed the
proteomic effects of siRNA-mediated depletion of the Sec62-interacting protein Sec63. We
identiﬁed a comprehensive list of differentially regulated proteins, providing new insights
into the molecular mechanisms of the cancer-related functions of Sec62 in cell migration,
drug resistance, and Ca2+-homeostasis.
© 2014 The Authors. Published by Elsevier B.V. on behalf of European ProteomicsD-DIGE
imentin
lastin 3
pithelial-mesenchymal transition
EMT)
Association (EuPA). This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
n recent studies, we identiﬁed and characterized SEC62 as a
otential new oncogene within the terminal 3q region that is
requently ampliﬁed in non-small cell lung cancer (NSCLC) [1].
e further found that SEC62 gene expression is signiﬁcantly
igher in squamous cell carcinoma (SCC) tumor tissue com-
ared to normal lung tissue, and that Sec62 protein content is
igniﬁcantly elevated in SCC and adenocarcinoma (AC) tumor
issue [1]. In the tissue samples of 70 patients with stage I–III
∗ Corresponding author. Tel.: +49 68411626515.
E-mail address: m.greiner@uks.eu (M. Greiner).
ttp://dx.doi.org/10.1016/j.euprot.2014.05.004
212-9685/© 2014 The Authors. Published by Elsevier B.V. on behalf of
rticle under the CC BY-NC-ND license (http://creativecommons.org/licNSCLC, we observed a correlation of Sec62 levels with clini-
cal parameters, including inﬁltration of the lymph nodes (N+
vs. N0 tumors) and tumor progression (G3 vs. G2 tumors) [1],
and clinical follow-up revealed a signiﬁcant survival beneﬁt
for patientswhose tumors exhibited lowSec62protein content
[2].
At the molecular level, Sec62 protein content is appar-
ently responsible for cancer cell migration and invasion [1,3],
and for partial protection of cancer cells against thapsigargin-
induced endoplasmic reticulum (ER) stress [4]. These phen-
otypes can be copied to non-cancerous HEK293 cells by
European Proteomics Association (EuPA). This is an open access
enses/by-nc-nd/3.0/).
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plasmid-driven over-expression of SEC62. We recently also
found an inﬂuence of Sec62 on cellular calcium homeostasis.
First siRNA-mediated Sec62 depletion leads to higher cytosolic
calciumconcentrations [4], and secondplasmid-based overex-
pression of a SEC62 gene containing a mutation in a potential
EF-hand motif results in the same molecular and cellular
phenotypes as seen in Sec62 depletion [2]. Furthermore, a
recent systematic gain- and loss-of-function screen in immor-
talized human mammary epithelial cells found that SEC62 is
a major cancer driver within the 3q26 amplicon [5].
In addition to our research with respect to the cancer-
related functions of Sec62, this protein has also been
investigated as an accessory component of the protein-
conducting Sec61-complex, which can directly interact with
ribosomes and thereby regulate translation [6]. Sec62 is
also reportedly involved in small protein secretion [7] and
post-translational translocation of ppcecA into the ER [8]. Fur-
thermore, regarding the interaction of Sec62 with Sec63, a
Hsp40 homologue protein known to directly bind Sec62 was
shown to be regulated by CK2-mediated phosphorylation [9].
Despite great progress in understanding the function of Sec62
in protein transport to the ER and in cancer cell biology, the
exact molecular mechanisms and signaling pathways behind
these functions remain largely unknown.
In our present study, we used the 2D-DIGE technique to
search for general proteomic alterations in SCC or AC tumors
of the lungversusnormal lung tissue. Since the tumor samples
were preselected with respect to their Sec62 protein content,
we further investigated whether such alterations depended
on Sec62 over-production. In cell culture experiments, we
speciﬁcally over-expressedaplasmid-encoded SEC62 and then
compared the data derived from the different sources. We also
present the complimentary results of studying the Sec62 inter-
actomeand the consequences of loss of Sec63, themajor Sec62
interaction partner.
2. Materials and methods
2.1. Cell cultures and tissue samples
The cell lines PC3 (DSMZ no. ACC 465), HEK293 (DSMZ no. ACC
305), and NIH3T3 (DSMC no. ACC 59) were cultured in DMEM
medium (Gibco Invitrogen) containing 10% FBS (Biochrom)
and 1% penicillin/streptomycin (PAA), at 37 ◦C in a humidiﬁed
environmentwith 5%CO2.We generatedHEK293 cell lines sta-
bly transfected with either a plasmid encoding the wild-type
SEC62 gene (pSEC62-IRES-GPF) or an empty control plasmid
(pIRES-GPF) aspreviously described [1]. Further cultivationand
all experiments using the stably transfected cell lines were
performed in normal growth medium containing 1% G418.
Tissue samples were obtained from 70 lung cancer patients
with pathologically conﬁrmed AC or SCC. These samples
were dissected by a pathologist, sorted into cancerous and
healthy portions, snap frozen, and stored at −80 ◦C. The can-
cer samples were veriﬁed to have >80% tumor cell content
by microscopic evaluation of HE-stained cryostat sections.
Samples were only used if the patients gave signed informed
consent, following the guidelines of the local ethics board.s 4 ( 2 0 1 4 ) 25–39
2.2. Protein quantiﬁcation in cultured cells by western
blot
To quantify proteins in the cell culture samples, lysates
of 2×105 cells per preparation were subjected to western
blot analysis using an afﬁnity-puriﬁed polyclonal rabbit anti-
body directed against the carboxy-terminal undecapeptide
of human Sec62, a rabbit anti-peptide antiserum directed
against CLIMP-63 (PSAKQRGSKGGHC plus CLFVKVEKIHEKV),
and an afﬁnity-puriﬁed polyclonal rabbit antibody directed
against Sec63N380. For loading controls, we also used a
polyclonal anti--actin (Sigma–Aldrich, A5441-.5ML) or anti-
GAPDH antibody (Santa Cruz Biotechnology, FL-335). Vimentin
was detected using an anti-Vimentin-Cy3 antibody conju-
gate (Sigma–Aldrich, C-9080). Bound primary antibodies were
visualized with an ECLTM Plex goat-anti-rabbit IgG-Cy5 (GE-
Healthcare, PA-45012) or ECLTM Plex goat-anti-mouse IgG-Cy3
conjugate (GE-Healthcare, PA-43010) and the Typhoon-Trio
imaging system (GE-Healthcare) with the Image Quant TL
software 7.0 (GE-Healthcare). The ratios of Sec62, Sec63, or
Vimentin to -actin or GAPDH were determined.
2.3. Immunoﬂuorescence staining
Immunoﬂuorescence double-staining was performed on sta-
bly transfected HEK293 cells cultured on glass slides in 6-cm
dishes. The cellswerewashedwith PBS, ﬁxed in formaldehyde
(3.7% in PBS) at room temperature for 8min, and permeabil-
ized with 0.2% Triton X-100 and 1% BSA in PBS on ice for
5min. Then the cells were washed with PBS three times, and
non-speciﬁc binding sites were blocked by incubation in BSA
(1% in PBS). Subsequently, the cells were incubated for 60min
with the above-described speciﬁc antibodies against Sec62
or Vimentin-Cy3, or with phalloidin-FITC (Life Technologies,
F-432). Sec62 was visualized using a secondary goat-anti-
rabbit-FITC antibody conjugate (Dianova, 111-095-144). Cell
nuclei were stained with DAPI.
2.4. Silencing of gene expression by siRNA
For gene silencing, 5×105 NIH3T3 cells were seeded per 6-cm
dish in normal culture medium. The cells were transfected
with SEC63 siRNA (GGGAGGUGUAGUUUUUUUAtt, Ambion),
SEC62 siRNA (GGCUGUGGCCAAGUAUCUUtt, Ambion), or con-
trol siRNA (AllStarsNeg. Control siRNA,Qiagen, 1027281) using
HiPerFect Reagent (Qiagen, 301807) following the manufac-
turer’s instructions. After 24, 72, and 144h, the medium was
changed and the cells were transfected again. Silencing efﬁ-
ciency was evaluated by western blot analysis.
2.5. Proteomic analysis by 2-D difference gel
electrophoresis (2D-DIGE)
HEK293 cells stably overexpressing SEC62 encoded on a
pSEC62-IRES-GFP-plasmid, as well as control cells transfected
with an empty pIRES-GFP control plasmid, were cultured for
24h in six independent 25-cm2 culture ﬂasks. The cells were
then trypsinized, harvested, counted, and washed twice with
PBS buffer. NIH3T3 cells were cultured and transfected with
Sec63 siRNAor control siRNAas described above. At 192h after
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Fig. 1 – Sec62 protein content in samples used for 2D-DIGE. (A) Using western blot analysis, Sec62 and -actin (loading
control) were quantiﬁed in all six biological replicates for the SCC and AC patient samples and in the HEK293 samples with
either the pSEC62-IRES-GFP plasmid or control vector. The Sec62/-actin ratio was calculated and termed rSec62. (B)
Western blot representing the six biological replicates of the SEC62-overexpressing (pSEC62-IRES-GFP) or
non-overexpressing (pIRES-GFP) HEK293-cells that were quantiﬁed in (A). (C) The pick-gel from each DIGE-series (SCC, AC
and HEK293 pSEC62-IRES-GFP) is shown; the picked spots are indicated by a red fringe and the picked areas are indicated by
yellow circles. (D) Statistic analysis by DeCyder-software 6.5 for each series of DIGE-gels resulted in the indicated mean fold
change ratio and the p-value. Here these data for each picked spot are blotted. (For interpretation of the references to color in
t f the
t
c
f
l
i
C
3
p
u
t
n
P
H
q
o
this ﬁgure legend, the reader is referred to the web version o
he ﬁrst transfection, the cells were trypsinized, harvested,
ounted, and washed twice with PBS buffer. Finally the cells
rom the overexpression and the silencing experiments were
yophilized and stored at −80 ◦C.
For each experimental approach, 106 cells were suspended
n 100L labeling buffer (7M Urea, 2M Thiourea, 65mM
HAPS, and 25mM Tris/HCl pH 8.75) and homogenized for
0 s in a MP FastPrep24 homogenizer. Then the proteins were
uriﬁed using a 2-D Clean-Up kit (Amersham) and quantiﬁed
sing a 2-D Quant kit (Amersham) following the manufac-
urer’s instructions. Tissue samples were snap frozen in liquid
itrogen, and mechanically lysed with a pestle and mortar.
roteins were then isolated using the illustra triplePrep kit (GE
ealthcare) following the manufacturer’s instructions, and
uantiﬁed as described.Six pooled samples were prepared from the tissue of 14 AC
r 16 SCC patients by mixing the isolated proteins from two or
hree patients for each sample. These samples were selectedarticle.)
based on their Sec62 protein content as determined by west-
ern blot analysis [1], resulting in a mean Sec62 overexpression
of 4.2-fold (SCC) or 2.3-fold (AC). From the same patients,
matched tumor-free tissue samples were also prepared and
pooled in the same manner. The protein extracts were mixed
with 0.4nmol of either Cy3, Cy5, or Cy2 ﬂuorescent dye (GE
Healthcare) per 50g total protein, and subsequently incu-
bated on ice for 30min. The reaction was stopped by adding
1mol l-lysine. In the DIGE analysis, tumor samples (either
SCC or AC) and tumor-free tissue samples were labeled with
Cy3 or Cy5 dye, and compared using a Cy2-labeled mixture of
both as an internal standard. We used six gels (representing
six biological replicates) comparing SCC to normal tissue, and
six gels comparing AC to normal tissue. Each gel included dye
swaps between tumor and normal tissue to avoid biases by
incommensurable labeling reactions.
Finally, the gels were scanned with a Typhoon Trio scanner
(GE Healthcare) at a resolution of 100m, and protein spots
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Table 1 – Proteins that are differently abundant in SCC and AC tumors of the lung compared to normal lung tissue of the
same patients.
Spot numbera Accession
numberb
Protein name Molecular
mass
emPAIc AV-Ratiod Tumor entity
590 P10809 60kDa heat shock protein,
mitochondrial
61,187 6.3 −2.6 AC
615 P10809 60kDa heat shock protein,
mitochondrial
61,187 19.9 −2.3 AC
630 P10809 60kDa heat shock protein,
mitochondrial
61,187 5.9 −1.6 AC
1479 P05388 60S Acidic ribosomal
protein P0
34,423 0.7 1.8 SCC
1613 P18124 60S Ribosomal protein L7 29,264 1.9 4.4 SCC
1642 P18124 60S ribosomal protein L7 29,264 1.6 3.4 SCC
922 P52209 6-Phosphogluconate
dehydrogenase,
decarboxylating
53,619 0.8 −1.9 SCC
937 P52209 6-Phosphogluconate
dehydrogenase,
decarboxylating
53,619 0.2 −1.8 SCC
982 P52209 6-Phosphogluconate
dehydrogenase,
decarboxylating
53,619 0.3 −2.0 SCC
428 P11021 78kDa glucose-regulated
protein
72,402 69.7 −2.3 AC
430 P11021 78kDa glucose-regulated
protein
72,402 17.7 −2.2 AC
442 P11021 78kDa glucose-regulated
protein
72,402 4.9 −1.8 AC
1179 P62736 Actin, aortic smooth muscle 42,381 2.1 2.4 SCC
1314 P62736 Actin, aortic smooth muscle 42,381 1.5 −3.8 SCC
1330 P62736 Actin, aortic smooth muscle 42,381 2.6 −2.7 SCC
1339 P62736 Actin, aortic smooth muscle 42,381 2.9 −2.7 SCC
1179 P60709 Actin, cytoplasmic 1 42,052 2.1 2.4 SCC
1314 P60709 Actin, cytoplasmic 1 42,052 1.3 −3.8 SCC
1330 P60709 Actin, cytoplasmic 1 42,052 2.6 −2.7 SCC
1339 P60709 Actin, cytoplasmic 1 42,052 2.9 −2.7 SCC
1150 P23526 Adenosylhomocysteinase 48,255 2.1 −1.7 SCC
649 Q01518 Adenylyl cyclase-associated
protein 1
52,325 2.6 −2.7 SCC
723 P05091 Aldehyde dehydrogenase,
mitochondrial
56,859 1.1 −2.0 AC
731 P05091 Aldehyde dehydrogenase,
mitochondrial
56,859 1.3 −2.6 AC
175 O43707 Alpha-actinin-4 105,245 0.6 −2.2 SCC
944 P06733 Alpha-enolase 47,481 3.7 −1.9 AC
949 P06733 Alpha-enolase 47,481 1.7 −1.9 AC
975 P06733 Alpha-enolase 47,481 1.1 −1.8 AC
994 P06733 Alpha-enolase 47,481 1.6 −2.2 AC
922 P06733 Alpha-enolase 47,481 13.7 −1.9 SCC
937 P06733 Alpha-enolase 47,481 1.9 −1.8 SCC
982 P06733 Alpha-enolase 47,481 10.2 −2.0 SCC
1019 P06733 Alpha-enolase 47,481 2.6 −1.6 SCC
1168 P06733 Alpha-enolase 47,481 0.5 −3.1 SCC
1192 P06733 Alpha-enolase 47,481 2.6 −3.3 SCC
1518 P07355 Annexin A2 38,808 2.7 1.7 SCC
924 P20073 Annexin A7 52,991 2.2 −1.6 AC
590 P03973 Antileukoproteinase 15,228 0.5 −2.6 AC
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– Table 1 (Continued)
Spot numbera Accession
numberb
Protein name Molecular
mass
emPAIc AV-Ratiod Tumor entity
1117 P13861 cAMP-dependent protein
kinase type II-alpha
regulatory subunit
45,832 0.2 −2.2 SCC
1626 P00915 Carbonic anhydrase 1 28,909 1.7 2.4 AC
1613 P00915 Carbonic anhydrase 1 28,909 2.7 4.4 SCC
1666 P00918 Carbonic anhydrase 2 29,285 2.6 2.7 AC
1642 P00918 Carbonic anhydrase 2 29,285 1.9 3.4 SCC
605 P04040 Catalase 59,947 1.8 2.0 SCC
539 P07357 Complement component
C8 alpha chain
66,832 0.3 2.1 SCC
636 P22528 Corniﬁn-B 10,337 0.8 2.0 SCC
1019 P31146 Coronin-1A 51,678 0.7 −1.6 SCC
1059 P22695 Cytochrome b-c1 complex
subunit 2, mitochondrial
48,584 0.5 −2.2 SCC
631 Q07065 Cytoskeleton-associated
protein 4
66,097 3.3 2.4 SCC
979 P81605 Dermcidin 11,391 0.7 −2.0 AC
1626 P81605 Dermcidin 11,391 1.2 2.4 AC
491 Q14195 Dihydropyrimidinase-
related protein
3
62,323 0.4 1.5 AC
710 Q99615 DnaJ homolog subfamily C
member 7
57,203 2.2 −4.5 SCC
949 P26641 Elongation factor 1-gamma 50,429 3.9 −1.9 AC
1091 P49411 Elongation factor Tu,
mitochondrial
49,852 1.8 −2.1 SCC
215 P14625 Endoplasmin 92,696 1.6 −1.7 AC
175 P14625 Endoplasmin 92,696 0.7 −2.2 SCC
2345 Q05315 Eosinophil
lysophospholipase
16,556 0.5 5.0 AC
781 Q16658 Fascin 55,123 2.0 −2.2 SCC
711 P02675 Fibrinogen beta chain 56,577 4.8 −1.9 SCC
433 P08107 Heat shock 70kDa protein
1A/1B
70,294 2.4 2.2 AC
437 P08107 Heat shock 70kDa protein
1A/1B
70,294 9.3 2.3 AC
461 P08107 Heat shock 70kDa protein
1A/1B
70,294 2.1 2.4 AC
482 P08107 Heat shock 70kDa protein
1A/1B
70,294 0.7 2.0 AC
488 P02790 Hemopexin 52,385 0.5 1.9 AC
484 P02790 Hemopexin 52,385 0.4 2.4 SCC
515 P02790 Hemopexin 52,385 0.4 2.1 SCC
615 P61978 Heterogeneous nuclear
ribonucleoprotein K
51,230 2.9 −2.3 AC
630 P61978 Heterogeneous nuclear
ribonucleoprotein K
51,230 1.1 −1.6 AC
605 P14866 Heterogeneous nuclear
ribonucleoprotein L
64,720 0.8 2.0 SCC
2234 Q71DI3 Histone H3.2 15,436 1.2 −1.6 AC
2339 P62805 Histone H4 11,360 1.2 5.2 AC
2360 P62805 Histone H4 11,360 0.7 5.0 AC
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– Table 1 (Continued)
Spot numbera Accession
numberb
Protein name Molecular
mass
emPAIc AV-Ratiod Tumor entity
2363 P62805 Histone H4 11,360 0.7 4.7 AC
2364 P62805 Histone H4 11,360 2.8 4.5 AC
2423 P62805 Histone H4 11,360 2.8 4.7 AC
2434 P62805 Histone H4 11,360 0.7 3.4 AC
2441 P62805 Histone H4 11,360 2.8 3.9 AC
2501 P62805 Histone H4 11,360 1.9 2.4 AC
2243 P62805 Histone H4 11,360 1.9 5.2 SCC
491 P01876 Ig alpha-1 chain C region 38,486 0.4 1.5 AC
484 P01876 Ig alpha-1 chain C region 38,486 0.3 2.4 SCC
599 P01876 Ig alpha-1 chain C region 38,486 0.9 1.8 SCC
610 P01876 Ig alpha-1 chain C region 38,486 0.9 2.2 SCC
643 P01876 Ig alpha-1 chain C region 38,486 0.9 2.5 SCC
730 P01857 Ig gamma-1 chain C region 36,596 1.2 −2.2 AC
731 P01857 Ig gamma-1 chain C region 36,596 1.2 −2.6 AC
730 P01859 Ig gamma-2 chain C region 36,505 0.8 −2.2 AC
908 P01861 Ig gamma-4 chain C region 36,431 0.8 1.7 SCC
723 P01764 Ig heavy chain V-III region
VH26
12,745 1.0 −2.0 AC
716 P01834 Ig kappa chain C region 11,773 1.8 2.1 SCC
369 P01871 Ig mu chain C region 49,960 1.2 1.7 SCC
1479 P50213 Isocitrate dehydrogenase
[NAD] subunit alpha,
mitochondrial
40,022 0.6 1.8 SCC
1518 P50213 Isocitrate dehydrogenase
[NAD] subunit alpha,
mitochondrial
40,022 2.0 1.7 SCC
994 O75874 Isocitrate dehydrogenase
[NADP] cytoplasmic
46,915 0.6 −2.2 AC
1091 O75874 Isocitrate dehydrogenase
[NADP] cytoplasmic
46,915 2.2 −2.1 SCC
461 Q03252 Lamin-B2 67,762 0.9 2.4 AC
482 Q03252 Lamin-B2 67,762 1.4 2.0 AC
488 Q03252 Lamin-B2 67,762 0.5 1.9 AC
599 Q03252 Lamin-B2 67,762 3.1 1.8 SCC
515 P09960 Leukotriene A-4 hydrolase 69,868 0.4 2.1 SCC
539 P09960 Leukotriene A-4 hydrolase 69,868 0.6 2.1 SCC
711 Q9HCC0 Methylcrotonoyl-CoA
carboxylase beta chain,
mitochondrial
61,808 2.9 −1.9 SCC
1275 O43684 Mitotic checkpoint protein
BUB3
37,587 1.1 −1.5 SCC
215 P59665 Neutrophil defensin 1 10,536 0.8 −1.7 AC
1275 P59665 Neutrophil defensin 1 10,536 0.8 −1.5 SCC
781 P43490 Nicotinamide
phosphoribosyltransferase
55,772 4.0 −2.2 AC
2234 P62937 Peptidyl-prolyl cis-trans
isomerase A
18,229 14.2 −1.6 AC
1059 P00558 Phosphoglycerate kinase 1 44,985 1.2 −2.2 SCC
437 P13797 Plastin-3 71,279 1.1 2.3 AC
636 P13797 Plastin-3 71,279 1.8 2.0 SCC
610 P02545 Prelamin-A/C 74,380 3.5 2.2 SCC
631 P02545 Prelamin-A/C 74,380 1.5 2.4 SCC
643 P02545 Prelamin-A/C 74,380 1.0 2.5 SCC
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– Table 1 (Continued)
Spot numbera Accession
numberb
Protein name Molecular
mass
emPAIc AV-Ratiod Tumor entity
1150 Q9UQ80 Proliferation-associated
protein 2G4
44,101 1.8 −1.7 SCC
716 O15460 Prolyl 4-hydroxylase
subunit alpha-2
61,263 1.4 2.1 SCC
2243 P05109 Protein S100-A8 10,885 2.0 5.2 SCC
710 P14618 Pyruvate kinase isozymes
M1/M2
58,470 0.9 −4.5 SCC
924 P50395 Rab GDP dissociation
inhibitor beta
51,087 9.1 −1.6 AC
944 P50395 Rab GDP dissociation
inhibitor beta
51,087 1.3 −1.9 AC
908 Q13228 Selenium-binding protein 1 52,928 0.9 1.7 SCC
369 P02787 Serotransferrin 79,294 20.8 1.7 SCC
433 P38646 Stress-70 protein,
mitochondrial
73,920 4.2 2.2 AC
649 Q99832 T-complex protein 1
subunit eta
59,842 3.5 −2.7 SCC
428 P40939 Trifunctional enzyme
subunit alpha,
mitochondrial
83,688 1.0 −2.3 AC
430 P40939 Trifunctional enzyme
subunit alpha,
mitochondrial
83,688 0.5 −2.2 AC
442 P40939 Trifunctional enzyme
subunit alpha,
mitochondrial
83,688 0.8 −1.8 AC
975 P08670 Vimentin 53,676 49.8 −1.8 AC
979 P08670 Vimentin 53,676 23.9 −2.0 AC
1117 P08670 Vimentin 53,676 2.9 −2.2 SCC
1168 P08670 Vimentin 53,676 0.9 −3.1 SCC
1192 P08670 Vimentin 53,676 1.3 −3.3 SCC
a The number given by the software DeCyder (GE-Healthcare).
b From the UniProt KD database (http://www.uniprot.org).
c The exponentially modiﬁed protein abundance index in the respective spot [10].
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ion 6.5) with the target spot number set to 2000. For further
nalysis, we selected spots meeting the following criteria:
resence in at least ﬁve out of six biological replicates (SCC
amples and cell cultures) or in four out of ﬁve biological
eplicates (AC samples); statistically signiﬁcant regulation in
ll replicates, with a p value<0.05; relative regulation of at
east 1.5-fold (higher or lower). All regulated spots matching
hese criteria were picked from the gel and analyzed by nano-
C-MS/MS. The resulting peptide sequences were assigned to
roteins based on a database search (IPI human database,
BI), and their emPAI-values [10] were calculated. From the
ist of regulated proteins in the tissue samples, keratins and
emoglobin subunits were dismissed. For all 2D-DIGE analy-
es, the proteins identiﬁed in each spot were arranged by the
mPAI-value and the two top listed proteins were selected for
he tables, which are presented here. The original data are
hown in the Supplement.tion in the tumor, a positive value for a down-regulation.
2.6. Co-immunoprecipitation
For co-immunoprecipitation, 6×108 HEK293 cells stably trans-
fected with the pSEC62-IRES-GFP plasmid were harvested,
suspended in 64mL lysis buffer containing 20mM HEPES/KOH
pH 7.55, 1.5mM MgCl2, 1mM EDTA, 150mM KCl, 0.65% CHAPS,
and protease inhibitor (12g/mL each pepstatin A, leupeptin,
antipain, chrymostatin, and 200M phenylmethylsulfonylﬂu-
oride). These cells were incubated for 1.5h at 4 ◦C for cell lysis,
and centrifuged at 257,000× g for 20min at 2 ◦C. Next, two
22.5mL aliquots of the supernatant were incubated overnight
at 4 ◦C: one with 0.5mg of an afﬁnity-puriﬁed polyclonal rab-
bit anti-peptide antibody directed against the COOH terminus
of human Sec62, and the other with 0.5mg of an afﬁnity-
puriﬁed polyclonal rabbit antibody directed against GST. Each
antibody was pre-bound to protein A/G sepharose mix (Fast-
ﬂow, GE Healthcare, 1:1). The suspension was subsequently
transferred into a column (Mobi-Tec). After collecting the
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Table 2 – Differently abundant proteins in HEK293 pSEC62-IRES-GFP cells compared to HEK293 pIRES-GFP cells.
Spot numbera Accession
numberb
Protein name Molecular mass emPAIc AV ratiod
1389 P10809 60kDa heat shock protein,
mitochondrial
61,187 1.85 −1.55
1448 P10809 60kDa heat shock protein,
mitochondrial
61,187 30.7 −1.53
1457 P10809 60kDa heat shock protein,
mitochondrial
61,187 8.02 −1.83
1325 P31939 Bifunctional purine biosynthesis
protein PURH
65,089 4.61 1.55
1258 P08107 Heat shock 70kDa protein 1A/1B 70,294 9.75 1.86
1259 P08107 Heat shock 70kDa protein 1A/1B 70,294 1.49 2.56
1258 P13797 Plastin-3 71,279 2.53 1.86
1259 P13797 Plastin-3 71,279 1.82 2.56
1473 P30153 Serine/threonine-protein phosphatase
2A 65kDa regulatory subunit A alpha
isoform
66,065 4.21 −1.57
1325 P31948 Stress-induced-phosphoprotein 1 63,227 14.41 1.55
1389 P08670 Vimentin 53,676 34.51 −1.55
1448 P08670 Vimentin 53,676 176.02 −1.53
1457 P08670 Vimentin 53,676 80.68 −1.83
1473 P08670 Vimentin 53,676 3.98 −1.57
a The number given by the software DeCyder (GE-Healthcare).
b From the UniProt KD database (http://www.uniprot.org).
c tive s
regula
The exponentially modiﬁed protein abundance index in the respec
d An n-fold regulation of the spot; a negative value stands for an up-
ﬂow-through, the column was washed three times with the
lysis buffer, and another three times with a washing buffer
containing 50mM Tris/HCl pH 7.4, 150mM NaCl, 5mM EDTA,
0.5% Nonidet P40, and the above-described protease inhibitor.
Eight 500-L fractions of the bound material were eluted
from the columns using washing buffer supplemented with
1mg/mL of the peptide against which the anti-Sec62 antibody
was directed to. The eluted proteins were precipitated follow-
ing the method described by Wessel [11], and then loaded
on a SDS gel and stained with Coomassie brilliant blue. Pro-
tein bands were subsequently analyzed by nano-LC–MS/MS.
The determined peptide sequences were assigned to proteins
based on a database search (IPI human database, EBI), and
emPAI-values [10] were calculated for each protein result. Pro-
teins identiﬁed for each band were arranged by emPAI-values
and the three top listed proteins were selected for the tables,
which are presented here. Here also the molecular mass of the
denatured protein was taken into consideration. The original
data are shown in the Supplement.
3. Results and discussion
3.1. Proteomic comparison of tumor and normal tissue
of the lung
In our ﬁrst approach, we investigated the proteomic alter-
ations in tumor samples derived from SCC or AC of the lung,
whichwere compared to tumor-free lung tissue from the same
patients.Weanalyzedpaired fresh-frozen tissue samples from
a total of 30 patients suffering from stage II or IIIA NSCLC (16
SCC and 14 AC) and undergoing surgical resection with a cura-
tive intention. This large number of patients allowed us topot [10].
tion in the tumor, a positive value for a down-regulation.
obtain statistically reliable data for each NSCLC subtype indi-
vidually. In lung cancer, the genomic region 3q25-26where the
SEC62 gene is located has been shown to be more frequently
ampliﬁed in squamous cell carcinoma (55–85%) compared to
adenocarcinoma (25–30%) [12,13]. Here we pooled the sam-
ples according to their previously determined Sec62 protein
content [1], creating six biological replicates, each including
tissue samples from two to four cases. The relative Sec62 pro-
tein content in each pooled sample was again determined by
western blot (Fig. 1).
Using the 2D-DIGE approach for the SCC samples, we found
73 spots representing 49 different proteins that were signiﬁ-
cantly regulated in tumor compared to tumor-free lung tissue
(relative protein abundance of 1.5-fold higher or lower) and
detected in at least 5 of 6 replicates. Of these proteins, 24 were
up-regulated and 25 were down-regulated. In the AC sam-
ples, we detected 59 spots representing 32 proteins meeting
the afore-mentioned criterion for relative regulation andbeing
present in at least 4 of 5 replicates. Of these proteins, 20 were
up-regulated and 11 down-regulated. Eleven proteins were
found to be signiﬁcantly regulated in both SCC and AC tissue;
ﬁve of the latter were up-regulated and six down-regulated,
and in all cases, the observed regulation tended toward the
same direction in both analyzed histological entities. Table 1
presents a detailed list of all identiﬁed proteins.
The protein dermcidin was found to be regulated in two
spots in AC tissue, but the direction of regulation remained
unclear, as one spot showed down-regulation (2.4-fold) while
the other showed up-regulation (2.0-fold). This phenomenon
might result from the post-translational modiﬁcation that has
been described for this protein, or from limited proteolysis
leading to several truncated peptides [14,15]. This 110 amino-
acid secretory protein almost meets the criteria for small
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Fig. 2 – Regulation of the Vimentin protein content and localization with and without SEC62 overexpression. (A) Sec62 and
Vimentin were analyzed in HEK293 cells with SEC62 overexpression (pSEC62-IRES-GFP) and without (p-IRES-GFP), using a
Cy3-coupled antibody directed against Vimentin and a rabbit anti-Sec62 antibody combined with a FITC-coupled anti-rabbit
antibody. (B) Sec62 and Vimentin protein levels in HEK293 cells were quantiﬁed by western blot analysis. (C) The amounts of
Sec62, Vimentin, and -actin or GAPDH (loading control) were quantiﬁed at different cell numbers (50,000, 75,000, 100,000,
125,000, 150,000, and 200,000 cells per lane), and the ratio of Sec62 or Vimentin to -actin and GAPDH was calculated. The
mean values of these ratios were compared between Sec62-overproducing (pSEC62-IRES-GFP) and non-overproducing
(pIRES-GFP) cells. (D) The linearity of the signal intensity was proofed for all proteins. (E) Vimentin and -actin protein
contents were quantiﬁed by western blot analysis of tumor tissue and normal lung tissue of two different SCC tumor
patients, and the ratio of Vimentin to -actin was calculated (rVimentin).
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aroteins that strongly depend on Sec62 for efﬁcient translo-
ation to the ER [7]. It also contains a large disordered region
ithin its N-terminal sequence [15], which might affect its
ranslocation to the ER [16]. Therefore, the accumulation of
odiﬁed or partially digested dermcidin derivates might be
ue to the inﬂuence of Sec62 on its translocation to the ER.
Among the regulated proteins, we also found an enrich-
ent of proteins involved in ER-stress response, such as
ndoplasmin and BiP. Two previous studies using 2D-DIGE
echnology show that BiP is differentially abundant in thyroid
ancer [17,18], and another important study demonstrates
crucial function of BiP in angiogenesis, and describes
his protein as an effective target molecule for cancer
nti-neovascular therapy [19]. Our present results also iden-
iﬁed proteins with known functions in cell migration
nd invasion, such as hemopexin and Hsp70 1A/1B, andcytoskeleton-associated proteins, such as Vimentin, fascin,
and cytoskeleton-associated protein 4 (CLIMP-63). Within
these proteins CLIMP-63 is of special interest as this pro-
tein is normally controlling the ER-shape and the anchoring
of microtubules to the ER in a phosphorylation and cell-
cycle dependent manner [20]. Studies investigating the effect
of synthetic inhibitors (olomoucine, roscovitine) of cyclin-
dependent kinases (CDK) on cancer cell proliferation and
p53 protein content in human cancer cells unexpectedly
found an increase of CLIMP-63 after olomoucine-treatment
[21,22]. Taken together, these results perfectly support our
previous ﬁndings that SEC62-overexpressing tumors have
a higher invasion potential and are protected against
thapsigargin-induced ER stress [1,3,4], as well as identify
new and previously known proteins that are regulated in
cancer.
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Fig. 3 – Sec62-dependent regulation of CLIMP-63 in SCC tumor samples and HEK293 cells. (A) The amounts of CLIMP-63 and
-actin (loading control) were analyzed by western blot analysis of tumor tissue and normal lung tissue from two different
SCC tumor patients. (B) The signal intensity from (A) was quantiﬁed, and the ratio of CLIMP-63 to -actin was calculated
(rCLIMP-63). (C) Sec62 and Vimentin protein levels were quantiﬁed by western blot analysis of HEK293 cells either after
Sec62 depletion by siRNA treatment compared to control siRNA transfected cells, or after SEC62 over-expression. (D) The
signal intensity from (C) was quantiﬁed, and the ratio of CLIMP-63 to -actin was calculated (rCLIMP-63). (E) The Sec62
protein content and the cellular localization of f-actin are shown by immunoﬂuorescence staining using a rabbit anti-Sec62
antibody combined with a FITC-coupled anti-rabbit antibody and a phalloidin-FITC conjugate. Cell nuclei were stained with
DAPI.
3.2. Speciﬁc alterations in the proteome of HEK293
cells induced by SEC62 overexpression
Next, we analyzed proteomic differences between HEK293
cells stably overexpressing a plasmid-encoded SEC62 gene
(pcDNA3-SEC62-IRES-GFP) and control cells transfected with
an empty–vector plasmid (pcDNA3-IRES-GFP). We used a non-
tumor-originated cell line in order to focus speciﬁcally on
proteomic alterations caused by the increased amount of
Sec62 protein. Within the six biological replicates used in 2D-
DIGE experiments, the relative Sec62 protein levels in the
SEC62-overexpressing cells ranged from 246 to 554% (Fig. 1).
As expected, we detected much fewer proteomic alterations
as compared to our analysis of tumor material. Table 2 shows
that we found only three spots (1258, 1259, and 1457) to be
consistently regulated in all six biological replicates. Among
these, we again identiﬁed Hsp70 1A/1B (1258 and 1259), which
is described in the literature as having anti-apoptotic and car-
cinogenic effects [23] and as being a driving force for cancer
cell migration and invasion [24,25]. We also identiﬁed plastin 3
(1258 and 1259), an actin-binding protein harboring a potential
calcium-binding site in its N-terminus, which was previouslydescribed as being down-regulated in A549 lung cancer cells
after apoptosis induction [26]. Finally, we found Vimentin
(1457), a well-established marker for epithelial-mesenchymal
transition (EMT) [27], which is known to be up-regulated in
many cancer entities-including lung cancer, where it is asso-
ciated with an unfavorable prognosis [27] and also considered
as a “druggable” molecular target [28]. When including spots
regulated in at least ﬁve of the six biological replicates, three
more could be selected (1389, 1448, and 1473). All of these
again represented Vimentin (1389 and 1448), and were reg-
ulated in the same direction as spot 1457. The third spot
(1473) also contained serine/threonine-protein phosphatase
2A regulatory subunit A, PP2A A. This was a very interest-
ing ﬁnding, because the interaction of Sec62 with Sec63 (a
known binding partner of Sec62 in the ER membrane) was
previously shown to depend on the phosphorylation status
of Sec63, which is phosphorylated by CK2 [9]-and PP2A is a
long-known antagonist of CK2 [29]. Additionally, PP2A muta-
tions reportedly increase the incidence of lung cancer in mice
[30]. In three of our six biological replicates, we identiﬁed
the stress-induced phosphoprotein 1 (Hop1 or STIP1, spot
1325), which also reportedly plays a role in carcinogenesis [31]
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Table 3 – Proteins that co-precipitated with Sec62 from HEK293 pSEC62-IRES-GFP cells.
Band numbera Accession
numberb
Protein name Molecular mass emPAI
4 Q92616 Translational activator
GCN1
294,967 0.54
6 P49815 Tuberin 202,591 0.07
8 P49815 Tuberin 202,591 0.12
10 P49815 Tuberin 202,591 0.1
12 Q8IX12 Cell division cycle and
apoptosis regulator protein
1
133,423 1.7
14 Q8IUD2 ELKS/Rab6-
interacting/CAST family
member 1
128,236 0.7
16 Q8IX12 Cell division cycle and
apoptosis regulator protein
1
133,423 1.28
18 Q14566 DNA replication licensing
factor MCM6
93,801 0.62
20 Q13033 Striatin-3 87,554 0.25
22 P13639 Elongation factor 2 96,246 0.65
24 P08238 Heat shock protein HSP
90-beta
83,554 0.85
26 O95202 LETM1 and EF-hand
domain-containing protein
1, mitochondrial
83,986 0.64
28 P11142 Heat shock cognate 71kDa
protein
71,082 1.06
30 P08107 Heat shock 70kDa protein
1A/1B
70,294 2.76
34 Q9H078 Caseinolytic peptidase B
protein homolog
79,193 0.63
36 P08670 Vimentin 53,676 9.18
38 Q99442 Translocation protein SEC62 46,175 3.26
40 Q5VTE0 Putative elongation factor
1-alpha-like 3
50,495 1.14
42 P60709 Actin, cytoplasmic 1 42,052 2.9
44 Q96HS1 Serine/threonine-protein
phosphatase PGAM5,
mitochondrial
32,213 0.48
46 P81605 Dermcidin 11,391 0.69
48 P04075 Fructose-bisphosphate
aldolase A
39,851 0.38
50 P35232 Prohibitin 29,843 0.37
52 O75323 Protein NipSnap homolog 2 33,949 0.32
54 O75323 Protein NipSnap homolog 2 33,949 0.32
a
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ra The number shown in Fig. 4.
b Refers to the UniProt KD database (www.uniprot.org).
nd is considered a prognostic biomarker in ovarian cancer
32].
Interestingly, the proteins Hsp70 1A/1B, Vimentin, and
lastin 3 were identiﬁed as regulated in AC and/or SCC
umor tissue as well as in SEC62-overexpressing HEK293 cells,
ith the regulation tending toward the same direction in
ll cases. Hence, for these proteins, we suggest that the
bserved regulation is Sec62dependent. Toverify this assump-
ion, we also examined the Vimentin protein content of the
EK293 cell lines used for 2D-DIGE analysis via western blot
nalysis and indirect immunoﬂuorescence. Analyzing SEC62-
verexpressing and non-overexpressing HEK293 cells with
his technique, we found slightly increased Vimentin signal
ntensity in the former (Fig. 2A). Western blot experiments
evealed a 1.2- to 1.4-fold increase of the Vimentin proteincontent in HEK293 cells harboring the wild-type SEC62 encod-
ing plasmid compared to the empty vector control (Fig. 2B). As
these values were on the borderline of western blot accuracy,
we carefully evaluated the signal linearity for Vimentin, -
actin, andGAPDH (Fig. 2D). The detection of Vimentin in tumor
samples conﬁrmed the increased Vimentin protein content in
tumor compared to normal lung tissue (Fig. 2E).
The same was true for CLIMP-63, a second cytoskeleton-
associated protein that exhibited differential abundance in
our SCC tumor sample approach but not in the DIGE analy-
sis using the HEK293-cells. We detected a strongly increased
signal in the SCC tumor samples, but hardly any signal in
normal lung tissue (Fig. 3A and C). To analyze whether this
regulation really depended on the Sec62 protein level, we stud-
ied the CLIMP-63 protein content in HEK293 cells treated with
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Fig. 4 – Co-immunoprecipitation of Sec62-interacting proteins. HEK293 cells stably transfected with the pSEC62-IRES-GFP
plasmid were harvested, lysed, and the supernatant was incubated with an afﬁnity-puriﬁed polyclonal rabbit anti-peptide
antibody directed against the COOH terminus of human Sec62 or GST. The suspension was subsequently transferred into a
column, washed, and eluted using washing buffer supplemented with 1mg/mL of the peptide against which the anti-Sec62
ollow
lyzedantibody was directed. The eluted protein was precipitated f
gel, and stained with Coomassie brilliant blue. Proteins ana
SEC62 siRNAor control siRNA, andwe found reducedCLIMP-63
protein content after Sec62 depletion. Furthermore, over-
expressionof SEC62 led to increasedCLIMP-63protein content.
These cells exhibited a second band with an increased
molecular weight, potentially indicating a post-translational
modiﬁcation (Fig. 3B and D). CLIMP-63 is regulated by phos-
phorylation during the cell cycle [20].
Thus, overproduction of Vimentin and CLIMP-63 indeed
depended on SEC62 overexpression inHEK293 cells. To directly
study the inﬂuence of Sec62 on the actin rearrangement indi-
cated by the regulation of this set of actin-interacting proteins,
we stained f-actin with a phalloidin-FITC conjugate in PC3
cells that were either untreated or transfected with control
siRNA or SEC62 siRNA. Our results revealed a rearrangement
of the f-actin from being localized rather near the plasma
membrane in the presence of Sec62, to being equally dis-
tributed throughout the cell after Sec62 depletion (Fig. 3E).
Thus, changes in calcium-induced actin rearrangement in the
absence of Sec62 might contribute to the strongly reduced
migration potential of these cells.
3.3. From the proteomic view to the interactome of
Sec62
In addition to the alterations in tumor tissue and in
SEC62-overexpressing cultured cells, we also studied the
Sec62 interactome in HEK293 cells stably overexpressing the
plasmid-encoded SEC62 gene. To this end, we performed co-
immunoprecipitation experiments using an afﬁnity-puriﬁed
antibody directed against the COOH-terminal undecapeptide
of Sec62 that was previously shown to be highly speciﬁc under
native and denaturing conditions [3]. Table 3 summarizes alling the method described by Wessel [11], loaded on a SDS
in 56–62 are included in the respective supplemental ﬁle.
proteins that co-precipitated with Sec62, and Fig. 4 shows the
respectiveCoomassie-stainedSDSgel. Our results showed two
Sec62-interacting proteins, Hsp70 1A/1B and Vimentin, both
of which had previously shown a differential abundance in
at least one of the tumor tissue samples and in the SEC62-
overexpressing HEK293 cells. The co-immunoprecipitation
results also showed several other proteins with functions
related to the cancer phenotypes induced by SEC62 over-
expression, including the cell division cycle and apoptosis
regulator protein 1 (CCAR1), which is described as a key regu-
lator of apoptosis signaling [33], and the ELKS/Rab6 interacting
protein (ERC-1), which is reportedly involved in the develop-
ment of papillary thyroid carcinoma [34].
Another highly interesting interaction partner of Sec62-
especially with respect to its regulatory function in ER calcium
homeostasis [2]-is striatin-3, a calmodulin binding [35] and
PP2A-interactingprotein [36–38]. Sec62 interactedwith LETM1,
which, like Sec62 itself, is an EF-hand-containing calcium-
binding protein; however, due to its location in the inner
mitochondrial membrane [39], it is unlikely that its interac-
tion with Sec62 is physiologically relevant. Prohibitin, which
was also found to interact with Sec62 in this assay, is
also located in the mitochondria but can be found in the
plasma membrane as well [40], making it a possible substrate
for Sec62-dependent membrane insertion. Prohibitin is also
linked to cancer-related functions, such as androgen recep-
tor signaling [41] and regulation of cell proliferation [42] and
apoptosis [43]. We also analyzed four bands, picked from the
eluate of the GST-antibody-column. In three of these bands
we found Hsp70 1A/1B, Vimentin and the putative elongation
factor 1-alpha-like 3, i.e., the same proteins as compared to
the Sec62-antibody-column. However, quantiﬁcation showed
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Fig. 5 – Overlapping results of different proteome studies.
The proteins found in at least two proteome studies are
shown in a Venn diagram. Proteins marked with an
re u pa open proteo
uch less interaction in the control (Fig. 4B) and so also these
andidates bound speciﬁc to Sec62. In summary, this approach
evealed several intersections of the Sec62 interactome with
he regulated proteins identiﬁed in the 2D-DIGE experiments,
s well as highlighted several interesting candidate proteins
n the context of cancer development, disease progression, or
etastasis.
.4. Depletion of Sec63 leads to overlapping proteomic
hanges
ext, we investigated the inﬂuence of Sec63 depletion on
he cellular proteome, as this protein is a known inter-
ction partner of Sec62 [9,44,45] and likewise part of the
rotein translocationmachinery in the ERmembrane. Further-
ore, the SEC63 gene is among the most frequently mutated
enes in hereditary nonpolyposis colorectal cancer-associated
mall-bowel cancer, and in sporadic cancers with frequent
icrosatellite instability [46,47]. Here we depleted the Sec63
rotein in NIH3T3 cells by repeated transfection with siRNA,
valuated the silencing efﬁciency by western-blot (supple-
entary Fig. S1A), and subsequently used the lysates of six
ndependent experiments for 2D-DIGE analysis. Interestingly,
e found only four spots to be regulated by more than 1.5-
old (t-test: p<0.5, appearance in more than 12 spot maps),
epresenting four different proteins: cytoskeleton associated
rotein 4 (CLIMP-63), tyrosyl tRNA-synthetase, WD repeat-
ontaining protein 1, and prelamin A/C (supplementary Table
1 and Fig. S1B). Two of the proteins (CLIMP-63 and prelamin
/C) thatwere signiﬁcantly up-regulateduponSec63depletion
ere also found to beup-regulated in the Sec62-overproducing
CC samples as compared to adjacent tumor-free lung tis-
ue. Thus, it appears that these opposite changes in the Sec62
r Sec63 protein content both lead to the same effect: up-
egulation. As CLIMP-63 is an integral ER-membrane protein
20,48] that inﬂuences themobility of ER translocon complexes
hrough its interactionwithmicrotubules [49], onemight spec-
late that Sec62/Sec63 functions in regulating its membrane
nsertion.
. Conclusions
roteomic studies represent a powerful tool for investigat-
ng the biological background of a disease on the molecular
evel, and thus providing the detailed mechanistic insights
ecessary for developing new therapeutic strategies. To over-
ome the individual disadvantages of single experimental
pproaches, here we studied the proteomes of different
EC62 overexpressing tumor types, including SCC and AC
f the lung, and of a more deﬁned cell culture system
peciﬁcally overexpressing SEC62.We investigated SEC62 over-
xpression because we previously characterized it as a new
andidate oncogene [1] and it has been characterized as a
ancer driver gene in NSCLC by others [5]. The results of the
resent study provide new insights into the complex molec-
lar background of the tumor-related functions of Sec62. We
dentiﬁed three proteins regulated in SCC and/or AC as well
s in the SEC62-overexpressing HEK293 cells-namely, HSP70
A/B, plastin-3, and Vimentin. Of these, HSP70 1A/B andasterisk also co-immunoprecipitated with Sec62.
Vimentin also co-immunoprecipitated with Sec62, indicating
a direct protein–protein interaction (Fig. 5). We suggest that
one or more of the observed cytoskeletal effects of SEC62
overexpression, together with altered calcium homeostasis,
contribute to the hallmarks of SEC62-overexpressing (tumor)
cells, i.e., increased migration potential and increased ER
stress tolerance.
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